Iron Therapy in Colo-Rectal Neoplasm and Iron Deficiency Anemia: Intravenous Iron Sucrose Versus Oral Ferrous Sulphate.
Recruitment status was: Not yet recruiting
Iron Deficiency Anemia
Drug: i.v. iron sucrose
Drug: Oral iron
|Study Design:||Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Randomized, Parallel Group, Clinical Trial Comparing Intravenous Iron Sucrose Versus Oral Ferrous Sulphate in the Treatment of Perioperative Iron Deficiency in Patients With Colo-Rectal Neoplasm and Iron Deficiency Anemia.|
- Preoperative variations in hemoglobin.
- Postoperative variations in hemoglobin.
- Blood transfusion needs (pre, intra and postoperative)
- Postoperative complications:
- - Pulmonary thromboembolism
- - Infections
- - Reintervention
- - Death
- Length of hospital stay
Most patients with colorectal neoplasm have iron deficiency, which can be triggered in the pre-operative period by a decrease of iron intake and the bleeding in the site of neoplasm.
In the postoperative period, iron deficiency can be aggravated by surgical bleeding.
Iron plays a leading rol in haemoglobin production, cell mitosis and immune system. Animal experimentation has shown that induced iron deficiency and mild anemia lead to postoperative mortality and lactacidemia in a model of peritonitis.
Moreover, anemia is the main risk factor to require intra and postoperative blood transfusions, and iron deficiency and anemia are associated to a larger number of postoperative complications (infections and longer hospital stay).
Oral iron therapy is the standard treatment in patients with preoperative iron deficiency, but iron levels inside red cells may not reach normality in time before surgery, and it can not be resumed until the patient can start again oral feeding.
In these patients, any increase in preoperative haemoglobin decreases the risk to need a blood transfusion during or after surgery.
This trial will compare standard oral iron and intravenous iron.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00199277
|Hospital Universitari Germans Trias i Pujol||Not yet recruiting|
|Badalona, Barcelona, Spain|
|Contact: Marta Piñol Pascual, MD|
|Principal Investigator: Marta Piñol Pascual, MD|
|Hospital Comarcal Sant Jaume de Calella.||Not yet recruiting|
|Calella, Barcelona, Spain|
|Contact: Dolors Vela Payán, MD|
|Principal Investigator: Dolors Vela Payán, MD|
|Fundació Hospital Asil de Granollers||Not yet recruiting|
|Granollers, Barcelona, Spain|
|Contact: Ramón López Ferré, MD|
|Principal Investigator: Ramón López Ferré, MD|
|Consorci Sanitari del Maresme||Not yet recruiting|
|Mataró, Barcelona, Spain|
|Contact: Alba Bosch Llobet, MD|
|Principal Investigator: Alba Bosch Llobet, MD|
|Hospital Miguel Servet||Not yet recruiting|
|Contact: José Antonio García-Erce, MD|
|Principal Investigator: José Antonio García-Erce, MD|
|Study Chair:||Pere Poch Martí, MD||Fundació Hospital-Asil de Granollers (Barcelona, Spain)|